Risankizumab was associated with more significant improvements among patients with plaque psoriasis when compared with other biologic therapies.

Two-thirds of patients with moderate or severe plaque psoriasis had complete or nearly complete clearance at 4 months with an oral peptide targeting interleukin (IL)-23, a randomized study showed. The ...

Apremilast improves disease severity and patient-reported outcomes among adults with psoriasis, regardless of genital involvement.

An expert discusses how the study assessed real-world effectiveness of tildrakizumab for moderate to severe plaque psoriasis, crucial for validating clinical trial results. Multisite data enhanced ...

Adults taking the novel once-daily oral pill for plaque psoriasis have significantly higher rates of clear or almost clear ...

Results from multiple Phase III trials of Icotrokinra in moderate-to-severe plaque psoriasis and a Phase IIb trial in ulcerative colitis successfully met all primary endpoints. Johnson & Johnson’s ...

The researchers highlighted that psoriasis is a systemic condition linked to various comorbidities, emphasizing the ...

The psoriasis market is estimated at $30 Billion by 2030 and has shifted significantly to oral drugsRamat Gan, Israel, March 24, 2025 (GLOBE ...

Topline results from Phase 3 ICONIC-ADVANCE 1&2�studies show icotrokinra achieved co-primary endpoints and showed superiority to deucravacitinib in moderate-to-severe plaque PsO ...

Please provide your email address to receive an email when new articles are posted on . Once-daily ICP-488 significantly improved PASI scores in patients with plaque psoriasis compared with ...